Head of the Securities practice group, Mark Wood is a highly skilled, pragmatic and client-focused practitioner with extensive experience representing public companies and investment banks in a wide variety of ongoing and transactional matters. These include IPOs and other public offerings of equity and debt securities, as well as mergers, acquisitions and other strategic transactions. Mark is also a leading advisor to institutional investors in highly structured private investment in public equity (PIPE) transactions.
Additionally, he frequently represents Canadian and other non-US companies and investment banks in cross-border capital raising and other matters.Clients appreciate Mark's deep experience and technical skill combined with his practical and commercial approach. For those reasons, they turn to him for assistance with their most complex corporate matters, including tender offers, mergers, acquisitions, going-private transactions and public and private capital raising transactions, as well as proxy contests and other shareholder activism matters. In addition, in his active PIPE practice Mark represents not only public companies but also institutional investors, including one of the largest and most prominent firms targeting the healthcare space.He also regularly counsels public companies on their securities law compliance, disclosure, corporate governance and compensation-related issues including the most challenging ones they face.Mark also represents pharmaceutical, medical device and other life sciences companies in a variety of transactional matters — he has particular expertise in the financing and commercialization of biosimilars.
Many of his clients are in the health care, technology, oil and gas, mining, manufacturing and financial services industries. Head of the Securities practice group, Mark Wood is a highly skilled, pragmatic and client-focused practitioner with extensive experience representing public companies and investment banks in a wide variety of ongoing and transactional matters. These include IPOs and other public offerings of equity and debt securities, as well as mergers, acquisitions and other strategic transactions.
Mark is also a leading advisor to institutional investors in highly structured private investment in public equity (PIPE) transactions. Additionally, he frequently represents Canadian and other non-US companies and investment banks in cross-border capital raising and other matters.Clients appreciate Mark's deep experience and technical skill combined with his practical and commercial approach. For those reasons, they turn to him for assistance with their most complex corporate matters, including tender offers, mergers, acquisitions, going-private transactions and public and private capital raising transactions, as well as proxy contests and other shareholder activism matters.
In addition, in his active PIPE practice Mark represents not only public companies but also institutional investors, including one of the largest and most prominent firms targeting the healthcare space.He also regularly counsels public companies on their securities law compliance, disclosure, corporate governance and compensation-related issues including the most challenging ones they face.Mark also represents pharmaceutical, medical device and other life sciences companies in a variety of transactional matters — he has particular expertise in the financing and commercialization of biosimilars. Many of his clients are in the health care, technology, oil and gas, mining, manufacturing and financial services industries. Head of the Securities practice group, Mark Wood is a highly skilled, pragmatic and client-focused practitioner with extensive experience representing public companies and investment banks in a wide variety of ongoing and transactional matters.
These include IPOs and other public offerings of equity and debt securities, as well as mergers, acquisitions and other strategic transactions. Mark is also a leading advisor to institutional investors in highly structured private investment in public equity (PIPE) transactions. Additionally, he frequently represents Canadian and other non-US companies and investment banks in cross-border capital raising and other matters.
Clients appreciate Mark's deep experience and technical skill combined with his practical and commercial approach. For those reasons, they turn to him for assistance with their most complex corporate matters, including tender offers, mergers, acquisitions, going-private transactions and public and private capital raising transactions, as well as proxy contests and other shareholder activism matters. In addition, in his active PIPE practice Mark represents not only public companies but also institutional investors, including one of the largest and most prominent firms targeting the healthcare space.
He also regularly counsels public companies on their securities law compliance, disclosure, corporate governance and compensation-related issues including the most challenging ones they face.Mark also represents pharmaceutical, medical device and other life sciences companies in a variety of transactional matters — he has particular expertise in the financing and commercialization of biosimilars. Many of his clients are in the health care, technology, oil and gas, mining, manufacturing and financial services industries.
